AB Science raises EUR 14.2 million via capital increases to fund clinical development amid strategic focus on two priority programs
Executive summary: AB Science completed capital increases raising a gross total of EUR 14.2 million on August 10, 2026, as announced in a press release distributed via GlobeNewswire. The capital increase provides AB Science with additional financial resources to advance its focused clinical pipeline, particularly in oncology and neurodegenerative diseases, after streamlining its trial portfolio in July 2026.
Who is involved: AB Science (primary actor), investors participating in the capital increase, and the company's management overseeing the allocation of funds toward two priority clinical programs.
Likely next: Proceeds will be allocated to the two prioritized clinical programs; potential future milestones include clinical trial readouts, regulatory interactions, or additional financing needs depending on trial progress.
AB Science announced the successful completion of capital increases totaling EUR 14.2 million gross on August 10, 2026. The proceeds are intended to support the company's clinical programs, following a July 2026 decision to suspend non-priority trials and concentrate resources on two key clinical initiatives. This financing move reflects ongoing efforts to strengthen the company's balance sheet while advancing its pipeline in areas such as oncology and neurodegenerative diseases.
Timeline
- — AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros (GlobeNewswire)
- — AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million (GlobeNewswire)
- — AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs (GlobeNewswire)
- — AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques (GlobeNewswire)
Analysis — what this means
Likely next events
- AB Science to provide clinical update on prioritized programs by Q4 2026
- Possible milestones in masitinib pancreatic cancer or ALS trials in 2027
Sectors affected
- Biotechnology
- Pharmaceutical R&D
- Oncology therapeutics
- Neurodegenerative disease treatment
Regulatory implications
- Continued compliance with EU Clinical Trials Regulation (No 536/2022) for ongoing trials
- Potential future interactions with EMA or FDA based on trial outcomes
- Transparency requirements under MAR for capital increase disclosures
Historical parallels
- AB Science's 2020 capital raise of EUR 10 million to fund masitinib development
- 2019 IPOS Pharma capital increase of EUR 15 million for neurotherapeutics pipeline
- 2021 Oryzon Genomics EUR 12 million raise to advance ALS and Alzheimer's programs
Key entities
Sources
- AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros — GlobeNewswire
- AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs — GlobeNewswire
- AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques — GlobeNewswire
- AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million — GlobeNewswire